MiRNAs in urine: A mirror image of kidney disease?

Expert Review of Molecular Diagnostics

Volumn 15, Issue 3, 2015, Pages 361-374

  Papadopoulos, Theofilos ^a,b   Belliere, Julie ^a,b   Bascands, Jean Loup ^a,b   Neau, Eric ^a,b   Klein, Julie ^a,b   Schanstra, Joost P ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

biomarker; canonical pathways; computational analysis; kidney; kidney disease; miRNA; urine

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA;

GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; KIDNEY DISEASES; METABOLISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; URINE;

BIOMARKERS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; KIDNEY DISEASES; MICRORNAS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84923365533     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1009449     Document Type: Review

References (164)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75(5):843-54
2. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75(5):855-62
3. Lee R, Feinbaum R, Ambros V. A short history of a short RNA. Cell 2004; 116(2 Suppl):S89-92
4. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403(6772):901-6
5. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 2011;717(1-2):1-8
6. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6(5):376-85
7. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11(3):228-34
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
9. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014;15(8):509-24
10. von Brandenstein M, Richter C, Fries JW. MicroRNAs: small but amazing, and their association with endothelin. Life Sci 2012; 91(13-14):475-89
11. Ambros V, Bartel B, Bartel DP, et al. A uniform system for microRNA annotation. Rna 2003;9(3): 277-9
12. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42(Database issue):D68-73
13. Jung M, Schaefer A, Steiner I, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010;56(6): 998-1006
14. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol 2012;7(9):1528-33
15. Cheng L, Sun X, Scicluna BJ, et al. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int 2014; 86(2):433-44
16. Haase M, Mertens PR. Biomarkers: more than just markers!. Nephrol Dial Transplant 2015;30(1):33-8
17. Yun SJ, Jeong P, Kim WT, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012;41(5):1871-8
18. Mall C, Rocke DM, Durbin-Johnson B, Weiss RH. Stability of miRNA in human urine supports its biomarker potential. Biomarkers Med 2013;7(4):623-31
19. Lv LL, Cao Y, Liu D, et al. Isolation and quantification of microRNAs from urinary exosomes/microvesicles for biomarker discovery. Int J Biol Sci 2013;9(10):1021-31
20. Fang DY, King HW, Li JY, Gleadle JM. Exosomes and the kidney: blaming the messenger. Nephrology (Carlton) 2013; 18(1):1-10
21. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014;32(1):41.e41-9
22. van Balkom BW, Pisitkun T, Verhaar MC, Knepper MA. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int 2011;80(11):1138-45
23. Beltrami C, Clayton A, Phillips AO, et al. Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans 2012; 40(4):875-9
24. Camussi G, Deregibus MC, Bruno S, et al. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010;78(9):838-48
25. Ramachandran S, Palanisamy V. Horizontal transfer of RNAs: exosomes as mediators of intercellular communication. Wiley Interdiscip Rev RNA 2012;3(2):286-93
26. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 2014;3:23743
27. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108(12):5003-8
28. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010;38(20):7248-59
29. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13(4):423-33
30. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39(16):7223-33
31. Aguilar AL, Piskol R, Beitzinger M, et al. The small RNA expression profile of the developing murine urinary and reproductive systems. FEBS Lett 2010;584(21):4426-34
32. Ma L, Qu L. The function of microRNAs in renal development and pathophysiology. J Genet Genomics 2013;40(4):143-52
33. Agrawal R, Tran U, Wessely O. The miR-30 miRNA family regulates Xenopus pronephros development and targets the transcription factor Xlim1/Lhx1. Development 2009;136(23):3927-36
34. Wessely O, Agrawal R, Tran U. MicroRNAs in kidney development: lessons from the frog. RNA Biol 2010;7(3):296-9
35. Nagalakshmi VK, Ren Q, Pugh MM, et al. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 2011; 79(3):317-30
36. Wu J, Zheng C, Fan Y, et al. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J Am Soc Nephrol 2014; 25(1):92-104
37. Krupa A, Jenkins R, Luo DD, et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010;21(3):438-47
38. Lu J, Kwan BC, Lai FM, et al. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton) 2012;17(4): 346-51
39. Ben-Dov IZ, Muthukumar T, Morozov P, et al. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012;94(11):1086-94
40. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014;85(1): 49-61
41. Kottgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009;41(6):712-17
42. Ecder T. Early diagnosis saves lives: focus on patients with chronic kidney disease. Kidney Int Suppl (2011) 2013;3(4):335-6
43. Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014;29(1):29-40
44. Neal CS, Michael MZ, Pimlott LK, et al. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011;26(11):3794-802
45. Ma K, Pan X, Fan P, et al. Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer 2014;13:118
46. Szeto CC, Ching-Ha KB, Ka-Bik L, et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Markers 2012;33(3):137-44
47. Wang H, Peng W, Ouyang X, Dai Y. Reduced circulating miR-15b is correlated with phosphate metabolism in patients with end-stage renal disease on maintenance hemodialysis. Ren Fail 2012;34(6):685-90
48. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012;21(4):410-16
49. Chau BN, Xin C, Hartner J, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012;4(121):121ra118
50. Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One 2013;8(2):e58014
51. Wang G, Kwan BC, Lai FM, et al. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol 2012; 36(5):412-18
52. Lv LL, Cao YH, Ni HF, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol 2013;305(8): F1220-7
53. Wang B, Koh P, Winbanks C, et al. miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 2011;60(1):280-7
54. Oba S, Kumano S, Suzuki E, et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One 2010; 5(10):e13614
55. Qin W, Chung AC, Huang XR, et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011;22(8):1462-74
56. Tang O, Chen XM, Shen S, et al. MiRNA-200b represses transforming growth factor-beta1-induced EMT and fibronectin expression in kidney proximal tubular cells. Am J Physiol Renal Physiol 2013;304(10): F1266-73
57. Fang Y, Yu X, Liu Y, et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-alpha activation. Am J Physiol Renal Physiol 2013;304(10):F1274-82
58. Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012; 23(2):252-65
59. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10(5):593-601
60. Xiong M, Jiang L, Zhou Y, et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 2012;302(3):F369-79
61. Conserva F, Pontrelli P, Accetturo M, Gesualdo L. The pathogenesis of diabetic nephropathy: focus on microRNAs and proteomics. J Nephrol 2013;26(5):811-20
62. Brosius FC 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 2008;9(4):245-54
63. Lan HY. Transforming growth factor-beta/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol 2012;39(8): 731-8
64. Argyropoulos C, Wang K, McClarty S, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 2013;8(1):e54662
65. Hou J, Shan Q, Wang T, et al. Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 2007; 282(23):17114-22
66. Shan SW, Lee DY, Deng Z, et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 2009;11(8):1031-8
67. Miller CG, Pozzi A, Zent R, Schwarzbauer JE. Effects of high glucose on integrin activity and fibronectin matrix assembly by mesangial cells. Mol Biol Cell 2014;25(16):2342-50
68. Padmashree DG, Swamy NR. Molecular signaling cascade of miRNAs in causing Diabetes Nephropathy. Bioinformation 2013;9(8):401-8
69. Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 2013; 8(11):e73798
70. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 2011; 4(2):197-205
71. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460(7256):705-10
72. Ghosh G, Subramanian IV, Adhikari N, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest 2010;120(11):4141-54
73. Chamorro-Jorganes A, Araldi E, Penalva LO, et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol 2011;31(11):2595-606
74. Martin MM, Lee EJ, Buckenberger JA, et al. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006;281(27): 18277-84
75. Louafi F, Martinez-Nunez RT, Sanchez-Elsner T. MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. J Biol Chem 2010;285(53):41328-36
76. Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107(7):3111-16
77. Liu Y, Gao G, Yang C, et al. Stability of miR-126 in Urine and Its Potential as a Biomarker for Renal Endothelial Injury with Diabetic Nephropathy. Int J Endocrinol 2014;2014:393109
78. Jiang S, Chuang PY, Liu ZH, He JC. The primary glomerulonephritides: a systems biology approach. Nat Rev Nephrol 2013; 9(9):500-12
79. Glassock RJ, Cohen AH. The primary glomerulopathies. Disease-a-month : DM. Mosby-Year Book; 1996;42(6):329-83
80. Szeto CC, Li PK. MicroRNAs in IgA nephropathy. Nat Rev Nephrol 2014; 10(5):249-56
81. Wang G, Kwan BC, Lai FM, et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010;28(2):79-86
82. Wang G, Kwan BC, Lai FM, et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers 2011;30(4): 171-9
83. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009;1792(6):497-505
84. Qu Z, Li W, Fu B. MicroRNAs in autoimmune diseases. BioMed Res Int 2014;2014:527895
85. Wang N, Zhou Y, Jiang L, et al. Urinary microRNA-10a and microRNA-30d serve as novel, sensitive and specific biomarkers for kidney injury. PLoS One 2012;7(12): e51140
86. Xue X, Feng T, Yao S, et al. Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. J Immunol 2011;187(11):5879-86
87. Chu JY, Sims-Lucas S, Bushnell DS, et al. Dicer function is required in the metanephric mesenchyme for early kidney development. Am J Physiol Renal Physiol 2014;306(7):F764-72
88. Li N, Kaur S, Greshock J, et al. A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res 2012;72(1): 154-64
89. Kumar M, Lu Z, Takwi AA, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011;30(7): 843-53
90. Ren H, Shen P, Li X, et al. Treatment and prognosis of primary focal segmental glomerulosclerosis. Contrib Nephrol 2013;181:109-18
91. Zhang W, Zhang C, Chen H, et al. Evaluation of MicroRNAs miR-196a, miR-30a-5P, and miR-490 as Biomarkers of Disease Activity among Patients with FSGS. Clin J Am Soc Nephrol 2014;9(9):1545-52
92. Sui W, Dai Y, Huang Y, et al. Microarray analysis of MicroRNA expression in acute rejection after renal transplantation. Transpl Immunol 2008;19(1):81-5
93. Zununi S, Ardalan M. MicroRNA and renal allograft monitoring. Nephrourol Mon 2013;5(3):783-6
94. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011;11(10): 2221-7
95. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283(23):15878-83
96. Lorenzen JM, Kielstein JT, Hafer C, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2011;6(7): 1540-6
97. Scian MJ, Maluf DG, David KG, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011;11(10):2110-22
98. Maluf DG, Dumur CI, Suh JL, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int 2014;85(2):439-49
99. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009;113(16):3754-64
100. Chaudhuri AA, So AY, Sinha N, et al. MicroRNA-125b potentiates macrophage activation. J Immunol 2011;187(10):5062-8
101. Medrano S, Monteagudo MC, Sequeira-Lopez ML, et al. Two microRNAs, miR-330 and miR-125b-5p, mark the juxtaglomerular cell and balance its smooth muscle phenotype. Am J Physiol Renal Physiol 2012;302(1):F29-37
102. Primo MN, Bak RO, Schibler B, Mikkelsen JG. Regulation of pro-inflammatory cytokines TNFalpha and IL24 by microRNA-203 in primary keratinocytes. Cytokine 2012;60(3):741-8
103. Sonda N, Simonato F, Peranzoni E, et al. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013;38(6): 1236-49
104. Huang B, Zhao J, Lei Z, et al. miR-142-3p restricts cAMP production in CD4+CD25-T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep 2009; 10(2):180-5
105. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33(4):1290-7
106. Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008;19(11): 2150-8
107. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol 2014;10(4): 193-207
108. Saikumar J, Hoffmann D, Kim TM, et al. Expression, circulation, and excretion profile of microRNA-21,-155, and-18a following acute kidney injury. Toxicol Sci 2012; 129(2):256-67
109. Ramachandran K, Saikumar J, Bijol V, et al. Human miRNome profiling identifies microRNAs differentially present in the urine after kidney injury. Clin Chem 2013; 59(12):1742-52
110. Li YF, Jing Y, Hao J, et al. MicroRNA-21 in the pathogenesis of acute kidney injury. Protein Cell 2013;4(11): 813-19
111. Lindsay MA. microRNAs and the immune response. Trends Immunol 2008;29(7): 343-51
112. Godwin JG, Ge X, Stephan K, et al. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci USA 2010;107(32):14339-44
113. Lan YF, Chen HH, Lai PF, et al. MicroRNA-494 reduces ATF3 expression and promotes AKI. J Am Soc Nephrol 2012;23(12):2012-23
114. Li Y, Fang X, Li QZ. Biomarker profiling for lupus nephritis. Genomics Proteomics Bioinformatics 2013;11(3):158-65
115. Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25(5):569-76
116. Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011; 70(8):1496-506
117. Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16(12): 939-46
118. Dai Y, Sui W, Lan H, et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009;29(7):749-54
119. Wang G, Tam LS, Li EK, et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 2010;37(12):2516-22
120. Wang G, Tam LS, Kwan BC, et al. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012;31(3): 435-40
121. Williams AE, Perry MM, Moschos SA, et al. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 2008; 36(Pt 6):1211-15
122. Pedersen I, David M. MicroRNAs in the immune response. Cytokine 2008;43(3): 391-4
123. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60(4):1065-75
124. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009;136(1):26-36
125. Borchers AT, Leibushor N, Naguwa SM, et al. Lupus nephritis: a critical review. Autoimmun Rev 2012;12(2):174-94
126. Tan YC, Blumenfeld J, Rennert H. Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs. Biochim Biophys Acta 2011; 1812(10):1202-12
127. Norman J. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta 2011;1812(10):1327-36
128. Schieren G, Rumberger B, Klein M, et al. Gene profiling of polycystic kidneys. Nephrol Dial Transplant 2006;21(7): 1816-24
129. Ben-Dov IZ, Tan YC, Morozov P, et al. Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS One 2014;9(1):e86856
130. Kawakami K, Enokida H, Chiyomaru T, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2012;48(6):827-36
131. Karihaloo A, Koraishy F, Huen SC, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011;22(10):1809-14
132. Swenson-Fields KI, Vivian CJ, Salah SM, et al. Macrophages promote polycystic kidney disease progression. Kidney Int 2013;83(5):855-64
133. Ta MH, Harris DC, Rangan GK. Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 2013;18(5):317-30
134. Lechuga S, Baranwal S, Li C, et al. Loss of gamma-cytoplasmic actin triggers myofibroblast transition of human epithelial cells. Mol Biol Cell 2014;25(20):3133-46
135. Available from: www.qiagen.com/ingenuity
136. Shen B, Liu X, Fan Y, Qiu J. Macrophages regulate renal fibrosis through modulating TGFbeta superfamily signaling. Inflammation 2014;37(6):2076-84
137. Di J, Jiang L, Zhou Y, et al. Ets-1 targeted by microRNA-221 regulates angiotensin II-induced renal fibroblast activation and fibrosis. Cell Physiol Biochem 2014;34(4): 1063-74
138. Correa-Costa M, Braga TT, Felizardo RJ, et al. Macrophage trafficking as key mediator of adenine-induced kidney injury. Mediators Inflamm 2014;2014:291024
139. Akao Y, Iio A, Itoh T, et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther 2011;19(2):395-9
140. Wang JY, Gao YB, Zhang N, et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-tomesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014; 392(1-2):163-72
141. Du R, Xia L, Ning X, et al. Hypoxia-induced Bmi1 promotes renal tubular epithelial cell-mesenchymal transition and renal fibrosis via PI3K/Akt signal. Mol Biol Cell 2014;25(17):2650-9
142. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012;82(5):516-24
143. Billeter AT, Hellmann J, Roberts H, et al. MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production. FASEB J 2014;28(12):5322-36
144. Santra M, Zhang ZG, Yang J, et al. Thymosin beta4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. J Biol Chem 2014;289(28):19508-18
145. Lyn-Cook BD, Xie C, Oates J, et al. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol Immunol 2014;61(1):38-43
146. Ichii O, Otsuka S, Sasaki N, et al. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int 2012;81(3): 280-92
147. Salama A, Fichou N, Allard M, et al. MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity. PLoS One 2014; 9(9):e106153
148. Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, et al. Suppressors of cytokine signaling regulate Fc receptor signaling and cell activation during immune renal injury. J Immunol 2004;172(11):6969-77
149. Kim MK, Maeng YI, Sung WJ, et al. The differential expression of TGF-beta1, ILK and wnt signaling inducing epithelial to mesenchymal transition in human renal fibrogenesis: an immunohistochemical study. Int J Clin Exp Pathol 2013;6(9):1747-58
150. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65
151. Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009;11(7): 881-9
152. Friedlander MR, Lizano E, Houben AJ, et al. Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol 2014;15(4):R57
153. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-66
154. Danborg PB, Simonsen AH, Waldemar G, Heegaard NH. The potential of microRNAs as biofluid markers of neurodegenerative diseases-a systematic review. Biomarkers 2014;19(4):259-68
155. Menghini R, Stohr R, Federici M. MicroRNAs in vascular aging and atherosclerosis. Ageing Res Rev 2014;17: 68-78
156. Pogue AI, Hill JM, Lukiw WJ. MicroRNA (miRNA); sequence and stability, viroid-like properties, and disease association in the CNS. Brain Res 2014;1584:73-9
157. Filip S, Pontillo C, Peter Schanstra J, et al. Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev Proteomics 2014;11(5):535-48
158. Li Z, Hassan MQ, Jafferji M, et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009;284(23): 15676-84
159. Zhao J, Tang N, Wu K, et al. MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PLoS One 2014;9(10):e108005
160. Amara S, Lopez K, Banan B, et al. Synergistic effect of pro-inflammatory TNFalpha and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. Mol Immunol 2015;64(1):26-35
161. Raamsteeboers AJ, Bogaard HJ, Vonk Noordegraaf A. Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient. Eur Respir Rev 2014; 23(131):147-9
162. Gao X, Cao Y, Staloch DA, et al. Bone morphogenetic protein signaling protects against cerulein-induced pancreatic fibrosis. PLoS One 2014;9(2):e89114
163. Konta T, Ichikawa K, Suzuki K, et al. A microarray analysis of urinary microRNAs in renal diseases. Clin Exp Nephrol 2014; 18(5):711-17
164. Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010;2(46): 46ps42